Diaceutics PLC Expanded lab network and data capabilities
February 27 2024 - 1:00AM
RNS Regulatory News
RNS Number : 5258E
Diaceutics PLC
27 February 2024
Diaceutics grows its lab
network and data capabilities in Europe
New data will deliver
enhanced insights to Diaceutics' customers and drive new sales
opportunities across multiple geographies
Belfast and
London, 27 February 2024 - Diaceutics PLC (AIM:
DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to
announce it has expanded its data supply network which will
significantly increase the number of labs through which Diaceutics
is sourcing data in Europe and will broaden the Company's European
data coverage. This data will accelerate the rollout of the DxRx
Signal product in key EU markets of Germany, France, Italy, Spain
and the United Kingdom (DxRx Signal has only previously been
offered by Diaceutics in the US market).
The increased data is now available to
Diaceutics customers enabling them to find more patients eligible
for their new and innovative therapies.
Jordan Clark,
Chief Data Officer of Diaceutics commented:
"This data will further
endorse our position as a leading provider of data to biotech and
pharma companies as they commercialize their products, find and
deliver therapies to patients across multiple
geographies."
This announcement contains inside
information for the purposes of Article 7 of Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of MAR.
The person responsible for making this announcement on behalf of
the Company is Nick Roberts, Chief Financial
Officer.
Enquiries:
Diaceutics PLC
|
Tel: +44 (0)28
9040 6500
|
Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial
Officer
Jordan Clark, Chief Data
Officer
|
investorrelations@diaceutics.com
|
|
|
Stifel Nicolaus Europe Limited (Nomad &
Broker)
|
Tel: +44
(0)20 7710 7600
|
Ben Maddison
|
|
Nick Harland
Kate Hanshaw
|
|
|
|
Alma
Strategic Communications
|
Tel: +44
(0)20 3405 0205
|
Caroline Forde
|
diaceutics@almastrategic.com
|
Kinvara Verdon
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the
right test and the right therapy to positively impact their disease
outcome. We provide the world's leading pharma and biotech
companies with an end-to-end commercialisation solution for
precision medicines through data analytics, scientific and advisory
services enabled by our platform DXRX - The Diagnostics Network
®.
DXRX is the world's first diagnostic
commercialisation platform for precision medicine, utilising a
global network of affiliate laboratories to deliver multiple
pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCDXGDDDBDDGSL
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Nov 2023 to Nov 2024